Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the United Kingdom

Paviour, Sophie, Hennig, Stefanie and Staatz, Christine E. (2016) Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the United Kingdom. Journal of Pharmacy Practice and Research, 46 1: 15-21. doi:10.1002/jppr.1145


Author Paviour, Sophie
Hennig, Stefanie
Staatz, Christine E.
Title Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the United Kingdom
Journal name Journal of Pharmacy Practice and Research   Check publisher's open access policy
ISSN 1445-937X
2055-2335
Publication date 2016-03
Sub-type Article (original research)
DOI 10.1002/jppr.1145
Open Access Status Not Open Access
Volume 46
Issue 1
Start page 15
End page 21
Total pages 7
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell
Collection year 2017
Language eng
Formatted abstract
Aim: To characterise usage and monitoring of intravenous tobramycin in cystic fibrosis (CF) patients in Australia and the UK.

Methods: An anonymous, online survey of healthcare professionals caring for CF patients was conducted. Survey questions were designed to obtain information on tobramycin dosing, therapeutic drug monitoring and toxicity monitoring.

Results: The survey was sent to pharmacists and clinicians in 73 CF centres. Responses were received from 32 and 40 healthcare professionals, from Australia and the UK, respectively. Once-daily dosing of tobramycin was the preferred administration regimen for 93.8 and 67.5% of participants in Australia and the UK, respectively. Among them 68.8% of Australian and 55% of UK participants initiated tobramycin therapy at a dose of 10 mg/kg/day or greater. Australian participants most commonly adjusted tobramycin dosage using log-linear regression analysis (40.6%) or trough measurements (28.1%). UK participants most commonly adjusted tobramycin dosage using trough (55%) or peak and trough measurements (37.5%). In 90.6% of Australian and 95% of UK participants practices, serum creatinine was routinely monitored during admission. Standard pure tone audiometry was performed by 15.6% of Australian and 17.5% of UK participants and high-frequency pure tone audiometry was performed by 15.6% of Australian and 10% of UK participants, once or twice a year.

Conclusions: Many discrepancies exist between Australia and the UK and within each country with respect to monitoring of intravenous tobramycin in CF patients. Greater ototoxicity monitoring is likely necessary in both countries. Further education of health professionals about the existence of national guidelines and guidance on how they can be applied in practice is likely required.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 19 Oct 2015, 16:12:22 EST by Dr Stefanie Hennig on behalf of School of Pharmacy